

Extracting large clots from large vessels without the need for thrombolytics or ICU stay

Inari Medical is committed to treating and transforming the lives of patients suffering from venous diseases through pioneering devices specifically designed and purpose-built for the venous anatomy and its unique clot morphology

CURRENT MARKETS AND PRODUCTS

Offering highly differentiated products in the venous space, treating Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE)

PULMONARY EMBOLISM (PE)

THE CHALLENGE:

- When part of a blood clot travels to the lungs causing a blockage
- 3rd leading cause of cardiovascular death¹
- Up to 15% 30-day all cause mortality^{2,3}, 28% for high-risk PE²
- Up to 50% of PE patients have residual vascular obstruction⁴⁻⁶, and long-term complications are common⁷

THE INARI SOLUTION:

The FlowTrierer[®] System

- A large bore catheter-based aspiration and mechanical thrombectomy system designed to remove large clots from large venous vessels, the right heart, pulmonary arteries and the lungs
- In May of 2018, the FlowTrierer System received FDA approved labeling, making it the first mechanical thrombectomy device indicated for the treatment of Pulmonary Embolism (PE)
- In January of 2021, FlowTrierer received 510(k) market clearance from the U.S. FDA for Right Atrial Clot in Transit becoming the first thrombectomy system not requiring a cardiopulmonary bypass circuit for blood clots in the right atrium

DEEP VEIN THROMBOSIS (DVT)

THE CHALLENGE:

- Blood clots that form in a deep vein, usually in the lower leg, thigh, or pelvis.
- Up to 50% of patients are expected to develop post-thrombotic syndrome (PTS)⁸
- Nearly 90% of PTS patients are unable to work 10 years after diagnosis⁹
- >10% of PTS patients develop venous leg ulcers¹⁰

THE INARI SOLUTION:

The ClotTrierer[®] System


- Designed to core, capture and remove large clots from large venous vessels
- In February of 2017, the ClotTrierer System received 510(k) market clearance from the U.S. FDA for the non-surgical removal of thrombi and emboli from the peripheral vasculature

FINANCIAL PROFILE

Robust quarterly revenue growth with gross margins of >80%

REVENUES

(LAST 8 QUARTERS, \$ IN MILLIONS)



1. Thrombolytic Efficacy in 2017: Increasing Options for Treating Ischemic Stroke, National Center for Biotechnology Information, May 2017.
 2. PEART: Comparison of Regimen of Oral Anticoagulation with 2 Oral Agents versus Parental PEART System, October 2022.
 3. Scharf et al. BMC Pulm Crit Care. 2019 Jun 11;19(1):202. doi: 10.1186/s12874-019-0503-3.
 4. Chopard et al. 2017. Arter Thromb Vasc Biol. Volume 17, Issue 11, 1822-1829.
 5. Mironov et al. 2020. Medicine. 99(16):e20193. doi: 10.1093/med/99/16/20193.
 6. Mirosook et al. Biomed Pap Med Sci Univ Palacký Olomouc Czech Repub. 2018;112(2):121-126. doi: 10.5507/bp.2018.001.
 7. Chou AK et al. West Med. 2017;42(2):113-117.
 8. Kahn SR et al. 2002. Medical Care. 40(12):1211-1218.
 9. Kahn et al. Arch Intern Med. 2004;164(11):1171-1176.
 10. Galisaud et al. Thromb Haemost. 2014;114(2):220-226.

FAST FACTS



PATIENT-FOCUSED

Pursuing extraordinary outcomes and improving the quality of life for patients since 2011



PRODUCT SIMPLICITY

Intuitive, easy-to-use, single-use devices that do not require capital equipment or the use of thrombolytic drugs



COMPELLING PROCEDURE ECONOMICS

Products designed for short, single sessions, eliminating the need for expensive thrombolytics which require costly ICU stays and carry risks of major bleeding



COMMITMENT TO CLINICAL DATA

Significant investment into real-world and broad evidence generation to drive adoption; studies and registries include FLARE, CLOUT, FLASH, FLAME, PEERLESS, and DEFIANCE



SCALING COMMERCIAL ORGANIZATION

Rapidly growing US sales team designed to help hospitals develop programs that systematically identify, triage and treat PE and DVT patients; international expansion commencing in Europe, Asia and Latin America



MARKET OPPORTUNITY

Combined addressable market of \$5.8B in the US alone, plus significant international opportunity



MARQUEE MED TECH IPO

1st non-biotech IPO post COVID-19 outbreak, completed May, 2020

(NASDAQ: NARI)

CONTACT INFORMATION

6001 Oak Canyon, Ste #100 Irvine, CA 92618, U.S.

Messeplatz 10, 4058 Basel, Switzerland

info@inarimedical.com

inarimedical.com